We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $6.66B
1-Year Est. Return 360.84%
This Fund
S&P 500
This Quarter Est. Return
+8.23%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$3.74B
AUM Growth
-$74.6M
Cap. Flow
-$193M
Cap. Flow %
-5.15%
Top 10 Hldgs %
49.32%
Holding
151
New
26
Increased
20
Reduced
26
Closed
34

Top Buys

Rank Stock Value
1
CRNX
Crinetics Pharmaceuticals
CRNX
+$76.8M
2
ATNX
Athenex, Inc. Common Stock
ATNX
+$47.1M
3
VRAY
ViewRay, Inc.
VRAY
+$35.6M
4
ARNA
Arena Pharmaceuticals Inc
ARNA
+$21.3M
5
IOVA icon
Iovance Biotherapeutics
IOVA
+$20.4M

Top Sells

Rank Stock Value
1
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$65.3M
2
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$64.5M
3
ALXN
Alexion Pharmaceuticals
ALXN
+$57.5M
4
HUM icon
Humana
HUM
+$36.8M
5
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$35.2M

Sector Composition

Rank Sector Weight
1 Healthcare 93.11%
2 Miscellaneous 5.71%
3 Consumer Staples 0.92%
4 Financials 0.17%
5 Consumer Discretionary 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DMK
101
DELISTED
DMK Pharmaceuticals Corporation Common Stock
DMK
$481K 0.01%
+1,964
New +$465K
MDGL icon
102
Madrigal Pharmaceuticals
MDGL
$12.1B
$474K 0.01%
2,213
-30,000
-93% -$7.53M
TARA icon
103
Protara Therapeutics
TARA
$222M
$469K 0.01%
6,012
-2,341
-28% -$216K
IMMU
104
DELISTED
Immunomedics Inc
IMMU
$444K 0.01%
+21,335
New +$505K
VCEL icon
105
Vericel Corp
VCEL
$2.03B
$385K 0.01%
27,211
– –
VCNX
106
DELISTED
Vaccinex, Inc. Common Stock
VCNX
$365K 0.01%
+238
New +$491K
HCM icon
107
HUTCHMED
HCM
$2.4B
$322K 0.01%
10,000
– –
CASI
108
DELISTED
CASI Pharmaceuticals
CASI
$204K 0.01%
4,368
– –
ONCS
109
DELISTED
OncoSec Medical Incorporated
ONCS
$70K ﹤0.01%
227
– –
GERN icon
110
CALL
Geron
GERN
$842M
$10K ﹤0.01%
+200,000
New +$872K
ONSIW
111
DELISTED
Oncobiologics, Inc. Series A Warrant Expiring 2/18/2019
ONSIW
$6K ﹤0.01%
+420,875
New +$10.4K
CAPR icon
112
Capricor Therapeutics
CAPR
$498M
$4K ﹤0.01%
400
– –
ADAP
113
DELISTED
Adaptimmune Therapeutics
ADAP
– –
-49,302
Closed -$585K
ADVM
114
DELISTED
Adverum Biotechnologies
ADVM
– –
-8,085
Closed -$428K
ASMB icon
115
Assembly Biosciences
ASMB
$532M
– –
-12,558
Closed -$5.91M
AXGN icon
116
Axogen
AXGN
$2.42B
– –
-165,000
Closed -$8.29M
CLSD
117
DELISTED
Clearside Biomedical
CLSD
– –
-47,172
Closed -$7.6M
COLL icon
118
Collegium Pharmaceutical
COLL
$711M
– –
-24,213
Closed -$577K
GERN icon
119
Geron
GERN
$842M
– –
-2,550,000
Closed -$11.1M
LKFT
120
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.83B
– –
-150,875
Closed -$13.9M
IMUX icon
121
Immunic
IMUX
$141M
– –
-375
Closed -$405K
NKTR icon
122
Nektar Therapeutics
NKTR
$2.28B
– –
-404
Closed -$296K
PBYI icon
123
Puma Biotechnology
PBYI
$477M
– –
-564,579
Closed -$27.7M
SGMO
124
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
– –
-25,000
Closed -$355K
SYRE icon
125
Spyre Therapeutics
SYRE
$8.02B
– –
-1,028
Closed -$272K
2 3 4
5
6

Similar funds

QP
Quilter Plc London, United Kingdom $6.65B AUM 37.83% 1-Year Est. Return
FCBT
First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return
RWM
Ritholtz Wealth Management New York $6.7B AUM 32.7% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.6B AUM 30.67% 1-Year Est. Return
WHRC
W.H. Reaves & Co Jersey City, New Jersey $6.59B AUM 31.9% 1-Year Est. Return
KGA
K5 Global Advisor Miami Beach, Florida $6.59B AUM
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $6.74B AUM 30.22% 1-Year Est. Return

Perceptive Advisors's Q3 2018 Portfolio in Review

As of Q3 2018, Perceptive Advisors held 151 positions worth $3.74B, down 2% from $3.81B the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Perceptive Advisors withdrew a net $193M in Q3 2018, closing 34 positions and reducing 26 holdings. Its most notable exit was Alexion Pharmaceuticals, an estimated $57.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, down from 94% a quarter earlier, followed by Miscellaneous and Consumer Staples.

Against the trend, Perceptive Advisors opened a new position in Crinetics Pharmaceuticals worth $74.1M.

  • Perceptive Advisors's largest Q3 2018 buy was Crinetics Pharmaceuticals: 2,587,953 shares worth $74.1M.
  • Perceptive Advisors added most to Athenex, Inc. Common Stock in Q3 2018, an estimated $47.1M increase.
  • Perceptive Advisors's biggest Q3 2018 reduction was Alnylam Pharmaceuticals, cutting an estimated $65.3M.
  • Perceptive Advisors fully exited Alexion Pharmaceuticals in Q3 2018, selling an estimated $57.5M.
  • Perceptive Advisors's ten largest holdings make up 49% of its $3.74B portfolio in Q3 2018.
  • Perceptive Advisors opened 26 new positions and closed 34 in Q3 2018.
  • Perceptive Advisors's portfolio value fell 2% quarter-over-quarter to $3.74B.

Based on Perceptive Advisors's 13F filing for Q3 2018, filed 14 Nov 2018.